Monopar Therapeutics Inc. Share Price & Technical Analysis
MNPR · $63.12 (+0.70%)
Healthcare / Biotechnology
$63.12
+0.70%
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressi…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
21% return in May, -11% avg return in past 3 year May month.
3% return in 2026, 169% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | -9% | 3% | -5% | 21% | – | – | – | – | – | – | – | 3% |
| 25 | 100% | -15% | 1% | 19% | -22% | 13% | 19% | -18% | 149% | 8% | 0% | -23% | 230% |
| 24 | 0% | 147% | -11% | -6% | -3% | 19% | -8% | -29% | 168% | 121% | 56% | -1% | 454% |
| 23 | 44% | -14% | -53% | -18% | -9% | -33% | -10% | -14% | -3% | -27% | -55% | 13% | -177% |
| 22 | -8% | 7% | -19% | -12% | -4% | 4% | -6% | -13% | -15% | 60% | 0% | -7% | -15% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$415.89M
P/E ratio
—
52W high
$105.0
52W low
$28.40
Volume
92,185
Beta
1.50
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Monopar Therapeutics Inc. share price today?
- Monopar Therapeutics Inc. (MNPR) last traded around $63.12 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MNPR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MNPR. Download the app for real-time alerts.
- How can I analyze Monopar Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.